The REDUCE Trial.

  title={The REDUCE Trial.},
  author={Fritz H. Schroeder and Monique J Roobol},
  journal={European urology},
  volume={58 2},
This trial investigated the value of the dual-action 5a-reductase inhibitor dutasteride (GlaxoSmithKline, Middlesex, UK) in 8231 men with prostate-specific antigen (PSA) values between 2.5 and 10 ng/ml who had undergone previous negative biopsies. Of these men, 6729 had at least one biopsy and were analyzed and presented as what the authors called the ‘‘restricted crude rate,’’ which, at all end points, was taken into consideration. The study resulted in a reduction of positive biopsies over a… CONTINUE READING